Every material Form 8-K Envista filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Envista reported third-quarter 2025 sales of $670 million, up 11.5% from a year earlier, and adjusted diluted EPS of $0.32 versus $0.12. The company posted a GAAP net loss of $30 million, driven by a tax charge tied to restructuring certain intercompany loans, and raised the low end of its full-year adjusted EPS guidance to $1.10 to $1.15.
Q3 2025 sales were $670 million, up from $601 million, with core sales growth of 9.4%.
GAAP net loss of $30 million, or $0.18 per diluted share, reflected a tax charge from restructuring certain intercompany loans; adjusted EPS was $0.32 versus $0.12.
Full-year 2025 adjusted diluted EPS guidance is $1.10 to $1.15, up from $1.05 to $1.15; core sales growth guidance is about 4%, up from 3% to 4%.
Repurchased 2.1 million shares for about $41 million in the quarter, leaving $108 million under the repurchase program.
Envista Holdings director Barbara B. Hulit submitted her resignation from the board on September 15, 2025, effective September 26, 2025. The company said she is leaving to pursue another opportunity and that the decision did not stem from any disagreement with the company on its operations, policies or practices.
Barbara B. Hulit resigned from the Envista board, effective September 26, 2025
Resignation submitted September 15, 2025; filing dated September 17, 2025
Company states she is leaving to pursue another opportunity, not due to a disagreement
Envista reported second-quarter 2025 sales of $682 million, up from $633 million a year earlier, and GAAP net income of $26 million, compared with a net loss of $1,152 million in the prior-year quarter that included a goodwill and intangible asset impairment. The company raised its full-year 2025 guidance, lifting core sales growth to 3% to 4% and adjusted diluted EPS to $1.05 to $1.15 from prior ranges of 1% to 3% and $0.95 to $1.05.
Q2 2025 sales were $682.1 million; core sales growth was 5.6%, and adjusted diluted EPS was $0.26, up from $0.11.
GAAP diluted EPS was $0.16 in Q2 2025, compared with a loss of $6.69 in Q2 2024.
Full-year 2025 adjusted diluted EPS guidance is $1.05 to $1.15, up from $0.95 to $1.05; core sales growth guidance is 3% to 4%, up from 1% to 3%.
During Q2 2025 the company repurchased 4.8 million shares for about $82 million and had $150 million remaining under its repurchase program.
Envista Holdings elected J. Andrew Pierce, Group President of Stryker's MedSurg & Neurotechnology group, to its board effective July 14, 2025, increasing the board from eight to nine members. He also joined the Audit Committee, which the board determined he is independent to serve on.
Pierce elected to the board effective July 14, 2025, with a term running until the 2026 Annual Meeting of Stockholders
Board increased from eight members to nine
Pierce joined the Audit Committee; the committee now includes Ms. Tsingos (Chair), Mr. Huennekens and Mr. Pierce
He will receive a pro-rated standard annual retainer for the rest of fiscal 2025, plus director equity awards and expense reimbursement
Envista reported first-quarter 2025 results for the quarter ended March 28, 2025, with sales of $617 million, down from $623.6 million a year earlier, and net income of $18 million, down from $23.6 million. The company said it is maintaining its full-year 2025 guidance, including core sales growth of 1% to 3% and adjusted EPS of $0.95 to $1.05.
Sales were $616.9 million versus $623.6 million in Q1 2024; core sales rose 0.2%.
Diluted EPS was $0.10 versus $0.14; adjusted diluted EPS was $0.24 versus $0.26.
Operating cash flow was $0.3 million and free cash flow was negative $5.1 million, compared with $40.3 million and $29.3 million a year earlier.
Full-year 2025 guidance was maintained, and $231 million remained under the repurchase program at quarter end after $19 million of Q1 buybacks.
Envista reported fourth-quarter 2024 sales of $652.9 million, up 1.1% from a year earlier, and GAAP net income of $1.2 million, compared with a loss of $217.4 million in the same quarter of 2023. Adjusted diluted EPS fell to $0.24 from $0.29, and adjusted EBITDA declined to $91.0 million, so headline profit measures moved in different directions. The company also issued full-year 2025 guidance and reported a full-year 2024 net loss of $1,118.6 million, driven by a $1,153.8 million goodwill and intangible asset impairment.
Q4 2024 sales were $652.9 million, with core sales up 2.0%; GAAP diluted EPS was $0.01 versus a loss of $1.27 a year earlier
Q4 2024 adjusted EBITDA was $91.0 million, down from $100.5 million, with a margin of 13.9% versus 15.6%
Full-year 2024 net loss was $1,118.6 million, including a $1,153.8 million goodwill and intangible asset impairment
2025 guidance calls for core sales growth of 1% to 3%, adjusted EBITDA margin of about 14%, and adjusted EPS of $0.95 to $1.05, compared with full-year 2024 adjusted EPS of $0.73
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Envista filing is on SEC EDGAR ↗. 8-K briefs of other companies →